Table 2. Summary of trials on treatment with IMRT technique.
| Author | Year (No. pt) | Type of Study | FU (median) | Risk groups (L/I/H) % | Tecnique | RT (Total dose/n.fz) (daily fz) | [EQ D2] a/b 1,5 |
ADT | Acute GU Toxicity % |
Acute GI Toxicity % |
Late GU Toxicity % |
Late GI Toxicity % |
Toxicity (Criteria) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fang et al | 2015 (213) | Prospective | 24 M | L:53;I:37;H:7,4 | IMRT CV |
79,2Gy/44(1.8) | [74.7Gy] | IMRT 66 (-);27(+) |
[IMRT] G0-G1:71,3; G2-G3:28,7 |
[IMRT] G0/G1:86,2;G2/G3:13,8 |
[IMRT] > G2:18,3 |
[IMRT] > G2:10,8 |
CTCAE |
| (181) | PBT CV |
PBT 79 (-);15(+) |
[PBT] G0-G1:78,7;G2-G3:21,3 |
[PBT] G0-G1:95,7;G2-G3:4,3 |
[PBT] > G2:12,8 |
[PBT] > G2:12,8 |
|||||||
| Goineau et al | 2013 (38) | Prospective | 54 M | L:18;I:60;H:32 | IMRT CV |
76Gy/38(2) | [76Gy] | 23(+) 15(-) |
G1:36,8;G2:5,3;G3:2,6 | G1:23,7;G2:5,3 G30 | G1:34,2;G2:5,3;G3:5,3 | G1:23,7;G2:15,8 | CTCAE |
| Marchand et al | 2010 (55) |
Prospective | 18 M | L:18; I:60,2; H:21,8 | IMRT CV |
76Gy/38(2) | [76Gy] | 25(+) 30(-) |
G2:38;G3:2 | G2:13 | G2:15 | G2:11 | CTCAE |
| Petrongari et al | 2013 (39) | Prospective phase II |
71 M | I:100 | IMRT CV |
86Gy/43(2) | [86Gy] | 39(-) | G2:51 | G2:44 | G2:5;G3:8 | G2:18;G3-G4:2,5% | CTCAE |
| Wu et al | 2012 (73) |
Prospective phase II |
54 M | L:25;I:75 | Hypo-IMRT IGRT (fiducials) |
55 Gy/16(3.43) | [77.6Gy] | 11(+) 62(-) |
G2:41;G3:3 | G2:34;G3:4 | G2:8 | G2:8 | RTOG |
| Zilli et al | 2011 (82) |
Prospective randomized phase III |
48 M | L:28; I:44;H:28 | Hypo-IMRT | 54Gy/14 (3.85) | [82.7Gy] | 11(+) 71 (-) |
G1:22;G2:4 | G1:8;G2:4 | G1:9;G2:5 | G1:13;G2:3 | RTOG |
| Lock et al | 2011 (66) |
Prospecitve phase II | 36 M | L:27;I:36; H:1 | Hypo-IMRT VMAT |
63,2Gy/20(3.16) | [84.1Gy] | 6(+) 60(-) |
G1:51,5;G2:33,8;G3:8,8 | G1:42,4;G2:25;G3:10,3; G4:1,5 |
G1:54,7;G2:14,1; G3:4,7 |
G1:39,1;G2:25;G3:3,1; G4:1,6. |
CTCAE |
| Martin et al | 2007 (92) |
Prospecitve phase II | 38 M | L:29;I:56; H:7 | Hypo-IMRT | 60Gy/20(3) | [77.1Gy] | 8(+) 84(-) |
G1:43;G2:25;G3:0 | G1:22;G2:11;G3:1 | G1:7;G2:3;G3:0 | G1:2;G2:4;G3:0 | RTOG |
| Randomized Studies for Meta-Analysis | |||||||||||||
| Dearnaley et al | 2016 (1065) |
Prospecitve randomized phase III |
62.4 M | L:15;I:73; H:12 | IMRT CV |
74Gy/37(2) | [74Gy] | 239(+) | G>2:46 | G>2:25 | G2:9.1; G>3:<1 | G2:13.7; G>3:0 | RTOG/ LENT |
| (1077) | Hypo-IMRT | 57Gy/19(3) | [73.3Gy] | G>2:46 | G>2:38 | G2:6.6; G>3:1 | G2:11.3; G>3:<1 | ||||||
| (1074) | Hypo-IMRT | 60Gy/20(3) | [77.1Gy] | G>2:49 | G>2:38 | G2:11.7; G>3:<1 | G2:13.7; G>3:<1 | ||||||
| Pollack et al | 2006 (50) |
Prospecitve randomized | 3 M | I:65; H:35 | IMRT CV |
76Gy/38(2) | [76Gy] | 44(+) 56(-) |
G1:28;G2:54;G3:2 | G1:40;G2:8;G3:0 | G1:31;G2:8;G3:0 | G1:12;G2:2;G3:0 | RTOG/ LENT |
| (50) | Hypo-IMRT | 70.2Gy/26(2.7) | [84.2Gy] | G1:44;G2:40;G3:8 | G1:40;G2:18;G3:0 | G1:30;G2:6;G3:0 | G1:16;G2:0;G3:0 | ||||||
| Pollack et al | 2013 (153) |
Prospecitve randomized | 68.4 M | L-I:50;H:50 | IMRT CV |
76Gy/38(2) | [76Gy] | 139(+) | G>2:5.2 | G>2:22.5 | G>2:14.6 | G1:58.9;G2:20.5;G3:2 | RTOG |
| (154) | Hypo-IMRT | 70.2Gy/26(2.7) | [84.2Gy] | G>2:10.6 | G>2:18 | G>2:15.3 | G1:53.7;G2:16.1;G3:2 | ||||||
Risk classes, technique used, total dose, type of fractionation, equivalent dose, acute and late gastrointestinal and genitourinary toxicity. Abbreviations: FU (Follow up); Risk groups: L (Low), I (Intermediate), H (High); CV (conventional); Hypo (Hypofractionated); IMRT (Intensity Modulated Radiation Therapy); PBT (Proton Beam Therapy); EQ (Equivalent Dose); CK (Cyberknife); EBRT (External Beam Radiation Therapy); IGRT (Image Guided Radiotherapy); GU (Genitourinary); GI (Gastrointestinal); ADT (androgen deprivation therapy).